Clinical trial
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With…
NCT00385827 · Centocor, Inc., Industry · Terminated
Key facts
| NCT number | NCT00385827 |
|---|---|
| Title | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) |
| Official title | A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Prostate |
| Intervention type | Drug |
| Interventions | Mitoxantrone, Siltuximab, Prednisone |
| Enrollment | 106 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Oct 11, 2006 |
| Last update posted | Aug 20, 2014 |
| Countries | Austria, Belgium, France, Germany, Spain, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: